Clinical perspectives on the role of the human papillomavirus vaccine in the prevention of cancer

Pharmacotherapy

Volumn 31, Issue 3, 2011, Pages 280-297

  Julius, Justin M ^a   Ramondeta, Lois ^a   Tipton, Katherine A ^a   Lal, Lincy S ^b   Schneider, Karen ^c   Smith, Judith A ^a,c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Ingenix Consulting   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Cancer prevention; Cervical cancer; HPV; Human papillomavirus; Vaccines

Indexed keywords

CAPSID PROTEIN L1; HEPATITIS A VACCINE; PLACEBO; WART VIRUS VACCINE;

ANGIONEUROTIC EDEMA; ANTIBODY TITER; ANUS CANCER; APPENDICITIS; ARTHRALGIA; ASTHMA; BRONCHOSPASM; CANCER INCIDENCE; CANCER PREVENTION; CANCER SCREENING; COST EFFECTIVENESS ANALYSIS; CROSS PROTECTION; DIZZINESS; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENCEPHALOMYELITIS; ERYTHEMA; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; GUILLAIN BARRE SYNDROME; HEAD AND NECK CANCER; HEADACHE; HUMAN; HYPERSENSITIVITY REACTION; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; MALAISE; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NEOPLASM; NEUROLOGIC DISEASE; NONHUMAN; OROPHARYNX CANCER; PANCREATITIS; PAPILLOMAVIRUS INFECTION; PENIS CANCER; PERSISTENT INFECTION; RASH; REVIEW; SEROCONVERSION; SKIN DISEASE; SPINAL CORD DISEASE; STUDY DESIGN; SYNCOPE; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VAGINA CANCER; VENOUS THROMBOEMBOLISM; VIRUS CARCINOGENESIS; VIRUS LIKE AGENT; VULVA CANCER; WART VIRUS;

ADOLESCENT; ADULT; ALPHAPAPILLOMAVIRUS; CHILD; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION; VAGINAL SMEARS; YOUNG ADULT;

EID: 79952378309     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.3.280     Document Type: Review

References (90)

1. Fleurence RL, Dixon JM, Milanova TF, et al. Review of the economic and quality-of-life burden of cervical human papillomavirus disease. Am J Obstet Gynecol 2007;196:206-12. (Pubitemid 46341227)
2. Insinga RP, Dasbach EJ, Elbasha EH, et al. Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives. Cancer Epidemiol Biomarkers Prev 2007;16:709-15.
3. Schiffman M, Castle PE. The promise of global cervical-cancer prevention. N Engl J Med 2005;353:2101-4. (Pubitemid 41653100)
4. Weinstock H, Berman S, Cates W Jr. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health 2004;36:6-10.
5. Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-8. (Pubitemid 28135669)
6. Sataiya M, Ahmed F, Krishnan S, et al. Cervical cancer incidence in a prevaccine era in the United States, 1998-2002. Obstet Gynecol 2007;109:360-70.
7. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19. (Pubitemid 29406813)
8. Smith JS, Backes DM, Hoots BE, et al. Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors. Obstet Gynecol 2009;13:917-24.
9. Koulovaa A, Tsui J, Irwina K, et al. Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008. Vaccine 2008;26:6529-41.
10. U.S. Food and Drug Administration. News release: FDA approves new vaccine for prevention of cervical cancer, October 16, 2009. Available from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm187048.htm. Accessed February 10, 2010.
11. U.S. Food and Drug Administration. News release: FDA approves new indication for Gardasil to prevent genital warts in men and boys, October 16, 2009. Available from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ 2009/ucm187003.htm. Accessed February 10, 2010.
12. Durst M, Gissmann L, Ikenberg H, zur Hausen H. A papilloma-virus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci 1983 80:3812-15.
13. zur Hausen H. Papillomavirus causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 2000;92:690-8.
14. Stanley M, Lowy DR, Frazer I. Chapter 12: prophylactic HPV vaccines: underlying mechanisms. Vaccine 2006;24:S106-13.
15. Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989;243:934-7. (Pubitemid 19066153)
16. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990;248:76-9.
17. Barbosa MS, Schlegel R. The E6 and E7 genes of HPV-18 are sufficient for inducing two-stage in vitro transformation of human keratinocytes. Oncogene 1989;4:1529-32. (Pubitemid 20008936)
18. Kahn J, Hillard P. Human papillomavirus and cervical cytology in adolescents. Adolesc Med Clin 2004;15:301-21. (Pubitemid 38900782)
19. Moscicki AB. HPV vaccines: today and in the future. J Adol Health 2008;43:S26-40.
20. Greer GP, Wheeler CM, Ladner MB, et al. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol 1995;33:2058-63.
21. Munoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27. (Pubitemid 36159887)
22. Stanley M. Immune responses to human papillomavirus. Vaccine 2006;24:S16-22.
23. Yugawa T, Kiyono T. Molecular mechanisms of cervical carcinogenesis by high-risk human papillomaviruses: novel functions of E6 and E7 oncoproteins. Rev Med Virol 2009;19:97-113.
24. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007;370:890-907. (Pubitemid 47371147)
25. Barr E, Sings HL. Prophylactic HPV vaccines: new interventions for cancer control. Vaccine 2008;26:6244-57.
26. Gustafsson L, Ponten J, Zack M, Adami HO. International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control 1997;8:755-63. (Pubitemid 27404646)
27. American Cancer Society. Cancer facts & figures 2010. Atlanta: American Cancer Society; 2009.
28. Worden FP, Hooton J, Lee J, et al. Association of tobacco use with risk of distant metastases, tumor recurrence, and death in patients with HPV-positive squamous cell cancer of the oropharynx [abstract]. J Clin Oncol 2009;27:S15.
29. National Cancer Institute, Surveillance Epidemiology and End Results. SEER fast stats: 5-year relative survival rates by year of diagnosis, by cancer site. Available from http://seer.cancer.gov/faststats/. Accessed March 17, 2010.
30. Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 2006;24:S11-25.
31. Frisch M, Glimelius B, van den Brule AJC, et al. Sexually transmitted infection as a cause of anal cancer. N Engl J Med 1997;337:1350-8. (Pubitemid 27467769)
32. Malek RS, Goellner JR, Smith TF, et al. Human papillomavirus infection and intraepithelial, in-situ, and invasive-carcinoma of penis. Urology 1993;42:159-70. (Pubitemid 23230862)
33. Daling JR, Madeleine MM, Johnson LG, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 2004;101:270-80. (Pubitemid 38890829)
34. Daling JR, Madeleine MM, Johnson LG, et al. Penile cancer: importance of circumcision, human papillomavirus and smoking in in situ and invasive disease. Int J Cancer 2005;116:606-16. (Pubitemid 41099198)
35. Salvioni R, Necchi A, Piva L, et al. Penile cancer. Urol Oncol 2009;27:677-85.
36. Dahlstrom KR, Adler-Storthz K, Etzel CJ, et al. Human papillomavirus type 16 infection and squamous cell carcinoma of the head and neck in neversmokers: a matched pair analysis. Clin Cancer Res 2003;9:2620-6. (Pubitemid 36842105)
37. Mellin-Dahlstrand H, Lindquist D, Bjornestal L, et al. P16(INK4a) correlates to human papillomavirus presence, response to radiotherapy and clinical outcome in tonsillar carcinoma. Anticancer Res 2005;25:4375-83.
38. Mendenhall WM, Logan HLC. Human papillomavirus and head and neck cancer. Am J Clin Oncol 2009;32:535-9.
39. Dayyani F, Etzel CJ, Liuet M, et al. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC) [online exclusive article]. Head Neck Oncol 2010;29:15. Available from http://www.headandneckoncology.org/content/2/1/15.
40. Burchell AN, Winer RL, Sanjose S, Franco EL. Chapter 6: epidemiology and transmission dynamics of genital HPV infection. Vaccine 2006;24:S52-61.
41. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003;157:218-26. (Erratum in Am J Epidemiol 2003;157:858.)
42. Stanley M. Prevention strategies against the human papillomavirus: the effectiveness of vaccination. Gynecol Oncol 2007;107:S19-23.
43. Manhart LE, Koutsky LA. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A metaanalysis. Sex Transm Dis 2002;29:725-35. (Pubitemid 35266418)
44. Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 2006;354:2645-54.
45. Holmes KK, Levine R, Weaver M. Effectiveness of condoms in preventing sexually transmitted infections. Bull World Health Organ 2004;82:454-61. (Pubitemid 38828432)
46. Wong EL, Roddy RE, Tucker H, et al. Use of male condoms during and after randomized, controlled trial participation in Cameroon. Sex Transm Dis 2005;32:300-7. (Pubitemid 40578070)
47. Kollar LM, Kahn JA. Education about human papillomavirus and human papillomavirus vaccines in adolescents. Curr Opin Obstet Gynecol 2008;20:479-83.
48. Tiro JA, Meissner HI, Kobrin S, et al. What do women in the U.S. know about human papillomavirus and cervical cancer? Cancer Epidemiol Biomarkers Prev 2007;16:288-94.
49. International Collaboration of Epidemiological Studies of Cervical Cancer. Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer 2006;118:1481-95.
50. Szarewski A, Jarvis MJ, Sasieni P, et al. Effect of smoking cessation on cervical lesion size. Lancet 1996;347:941-3. (Pubitemid 26102551)
51. International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies. Int J Cancer 2006;119:1108-24.
52. Smith JS, Green J, Berrington de Gonzalez A, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003;361:1159-67. (Pubitemid 36401593)
53. Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16/18 L1 virus like particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007;298:743-53. (Pubitemid 47263157)
54. Merck & Co., Inc. Gardasil (human papillomavirus quadrivalent [types 6, 11, 16, and 18] vaccine, recombinant suspension for intramuscular injection) product information. Whitehouse Station, NJ; 2009.
55. GlaxoSmithKline. Cervarix (human papillomavirus bivalent vaccine, recombinant intramuscular injection) product information. Research Triangle Park, NC; 2009.
56. Schmiedeskamp MR, Kockler DR. Human papillomavirus vaccines. Ann Pharmacother 2006;40:1344-52. (Pubitemid 44204965)
57. Ault KA; for the Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomized clinical trials. Lancet 2007;369:1861-8.
58. Villa LL, Costa RLR, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-8.
59. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43.
60. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.
61. Paavonen J, Naud P, Salmerón J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009;374:301-14.
62. Mao C, Koutsky LA, Ault KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006;107:18-27.
63. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet 2006;367:1247-55.
64. Harper D, Gall S, Naud P, et al. Sustained immunogenicity and high efficacy against HPV-16/18 related cervical neoplasia: long-term follow up through 6.4 years in women vaccinated with Cervarix (GSK's HPV 16/18 AS04 candidate vaccine). Presented at the 39th annual meeting on women's cancer of the Society of Gynecologic Oncologists, Tampa, FL, March 9-12, 2008.
65. The FUTURE II Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis 2007;196:1438-46.
66. Olsson SE, Villa LL, Costa RL, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007;25: 4931-9. (Pubitemid 46843434)
67. Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007;298:743-53. (Pubitemid 47263157)
68. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006;95:1459-66. (Pubitemid 44863348)
69. Mejia AF, Culp TD, Cladel NM, et al. Preclinical model to test human papillomavirus virus (HPV) capsid vaccines in vivo using infectious HPV/cottontail rabbit papillomavirus chimeric papillomavirus particles. J Virol 2006;80:12393-7. (Pubitemid 44904390)
70. Ekstrand ML, Coates TJ. Maintenance of safer sexual behaviors and predictors of risky sex: the San Francisco men's health study. Am J Public Health 1990;27:973-7. (Pubitemid 20239419)
71. Villa LL, Ault KA, Giuliano AR, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 2006;24:5571-83.
72. Koutsky LA, Harper DM. Chapter 13: current findings from prophylactic HPV vaccine trials. Vaccine 2006:24(suppl 3):114-21.
73. Smith JF, Brownlow M, Brown M, et al. Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions. Hum Vaccin 2007;3:109-15. (Pubitemid 47501028)
74. Hollinger FB. Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations. Am J Med 1989;87:S36-40.
75. Reisinger KS, Block SL, Lazcano-Ponce E, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 2007;26:201-9.
76. Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006;118:2135-45.
77. Pedersen C, Petaja T, Strauss G, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007;40:564-71. (Pubitemid 46771257)
78. Adolescents Study Investigators Network. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women. J Adolesc Health 2010;46:142-51.
79. HPV Vaccine Study Investigators for Adult Women. Human papillomavirus (HPV) 16/18 l1 AS04 virus-like particle (VLP) cervical cancer vaccine is immunogenic and well-tolerated 18 months after vaccination in women up to age 55 years [abstract]. J Clin Oncol 2007;25(June 20 suppl):3007.
80. Herzog TJ, Huh WK, Downs LS, et al. Initial lessons learned in HPV vaccination. Gynecol Oncol 2008;109:S4-11.
81. Waller J, Marlow LAV, Warde J. Mothers attitudes toward preventing cervical cancer through human papillomavirus vaccination: a qualitative study. Cancer Epidemiol Biomarker Prev 2006;15:1257-61. (Pubitemid 44125278)
82. Schwarz TF. An AS04-containing human papillomavirus (HPV) 16/18 vaccine for prevention of cervical cancer is immunogenic and well-tolerated in women 15-55 years old [abstract]. J Clin Oncol 2006;24(June 20 suppl):1008.
83. Petaja T, Keranen H, Karppa T, et al. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. J Adolesc Health 2009;44:33-40.
84. Shikarya T, Bernsteina D, Jin Y, et al. Epidemiology and risk factors for human papillomavirus infection in a diverse sample of low-income young women. J Clin Virol 2009;46:107-11.
85. Franco EL, Cuzick J, Hildesheim A, Sanjose S. Chapter 20: issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 2006;24(suppl 3):S171-7.
86. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004;96:604-15. (Pubitemid 38584984)
87. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007;13:28-41. (Pubitemid 46057835)
88. Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis 2008;14:244-51. (Pubitemid 351213674)
89. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008;359:821-32.
90. Kim JJ, Goldie SJ. Cost-effectiveness analysis of including boys in a human papillomavirum vaccination programme in the United States [online exclusive article]. BMJ 2009;339:b3884. Available from http://www.bmj.com/ content/339/bmj.b3884.long.